Fate Therapeutics (FATE) Stock Forecast, Price & News

Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

Is Fate Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fate Therapeutics stock.
View analyst ratings for Fate Therapeutics or view top-rated stocks.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Fate Therapeutics.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.08. The biopharmaceutical company earned $18.40 million during the quarter, compared to the consensus estimate of $9.01 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 34.89% and a negative net margin of 368.76%. The firm's quarterly revenue was up 65.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.48) earnings per share.
View Fate Therapeutics' earnings history.

What price target have analysts set for FATE?

9 equities research analysts have issued 1 year price objectives for Fate Therapeutics' shares. Their forecasts range from $60.00 to $116.00. On average, they anticipate Fate Therapeutics' share price to reach $87.22 in the next year. This suggests a possible upside of 267.6% from the stock's current price.
View analysts' price targets for Fate Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the following people:

• Mr. J. Scott Wolchko, Founder, CEO, Pres & Director (Age 52, Pay $926.25k) (LinkedIn Profile)
• Mr. Edward J. Dulac III, CFO & Principal Accounting Officer (Age 46, Pay $476.25k) (LinkedIn Profile)
• Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 49, Pay $585k) (LinkedIn Profile)
• Dr. Bahram Valamehr Ph.D., Chief R&D Officer (Age 45, Pay $585k)
• Dr. Mark Plavsic D.V.M., Ph.D., Chief Technical Officer
• Mr. Jim Beitel M.B.A., Sr. VP of Corp. Devel.
• Dr. Sarah Cooley, Sr. VP of Clinical Translation
• Dr. Yu-Waye Chu M.D., Chief Medical Officer
• Dr. Jerome Bressi Ph.D., Sr. VP of Regulatory Affairs & Quality Assurance

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics CEO Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among Fate Therapeutics' employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Fate Therapeutics' key competitors?

Some companies that are related to Fate Therapeutics include Repligen (RGEN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Halozyme Therapeutics (HALO), Ginkgo Bioworks (DNA), CRISPR Therapeutics (CRSP), Novavax (NVAX), Ablynx (ABLYF), Abcam (ABCM), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Iovance Biotherapeutics (IOVA), Relay Therapeutics (RLAY) and Twist Bioscience (TWST).
View all of FATE's competitors.

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.40%), Vanguard Group Inc. (7.96%), BlackRock Inc. (7.35%), Bellevue Group AG (3.70%), State Street Corp (3.59%) and Artal Group S.A. (2.07%). Company insiders that own Fate Therapeutics stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Redmile Group, Llc and Yu-Waye Chu.
View institutional ownership trends for Fate Therapeutics.

Which institutional investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, SG Americas Securities LLC, Bellevue Group AG, Goldman Sachs Group Inc., Ally Bridge Group NY LLC, Citigroup Inc., JPMorgan Chase & Co., and Principal Financial Group Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, and Yu-Waye Chu.
View insider buying and selling activity for Fate Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Fate Therapeutics stock?

FATE stock was acquired by a variety of institutional investors in the last quarter, including Deep Track Capital LP, State Street Corp, ARK Investment Management LLC, Brown Advisory Inc., Eversept Partners LP, Artal Group S.A., Invesco Ltd., and Comerica Bank.
View insider buying and selling activity for Fate Therapeutics or or view top insider-buying stocks.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $23.73.

How much money does Fate Therapeutics make?

Fate Therapeutics has a market capitalization of $2.29 billion and generates $55.85 million in revenue each year. The biopharmaceutical company earns $-212.15 million in net income (profit) each year or ($2.430010) on an earnings per share basis.

How many employees does Fate Therapeutics have?

Fate Therapeutics employs 449 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is www.fatetherapeutics.com.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at [email protected].